Bacterial Sepsis
6
1
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis
The Role of Decortication in Complex Empyema Cases: Multidrug Resistance and Tuberculosis at the Forefront
Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis
Blood Volume Assessment in COVID-19 and Bacterial Sepsis
Study of Low Carbohydrate Enteral Nutrition in Patients With Bacterial Septic Shock
Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant